KZIA:NASDAQKazia Therapeutics Limited analysis
Data as of Sep 26, 2026 - not real-time
- Latest price
- $9.57
- Risk: high
- 9/10High risk
Summary
Kazia Therapeutics Limited trades at $9.57, with its moving averages tangled rather than clearly stacked — a neutral trend structure. The last 30 days have lost 27.6%. With RSI at 35.3 the momentum picture is approaching oversold, alongside a bearish MACD signal. Price has been bracketed by support at $9.01 and resistance at $15.50.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 198.1% above today's level. Revenue is growing at 312.4%.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 103.4%, a beta of 2.26 and a maximum drawdown of 68.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 198.1% above today's level. Revenue is growing at 312.4%.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 103.4%, a beta of 2.26 and a maximum drawdown of 68.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Top market events
- Kazia Therapeutics Limited NASDAQ: KZIA "Kazia" or the "Company" , an oncology-focused biotechnology company developing...
- Kazia Therapeutics Limited NASDAQ: KZIA "Kazia" or the "Company" , an oncology-focused biotechnology company developing...
- Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the...
Market outlook
Short term
< 1 yearNeutral
Model confidence2/102 out of 10
Key factors
- Trading below the 200-day average of 10.54
- MACD momentum is negative
- 30-day price change of -27.6%
Medium term
1–3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Trading below the 200-day average of 10.54
- Analyst targets imply +198.1% versus the current price
- 30-day volatility of 103.4%
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +198.1% versus the current price
- Negative return on equity of -106.9%
- Revenue growth of +312.4%
Key metrics
Financial health
Revenue Growth312.40%
P/E Ratio-786.2
ROE-106.90%
ROA-25.70%
Debt/Equity0.21
P/B Ratio3.3
Op. Cash Flow$-14398379
Free Cash Flow$1.1M
Industry P/E30.5
Technical analysis
TrendNeutral
RSI35.3
Support$9.01
Resistance$15.50
MA 20$11.33
MA 50$12.56
MA 200$10.54
MACDBearish
VolumeDecreasing
Fear & Greed Index94.88
Valuation
Fair Value$9.20
Target Price$28.53
Upside/Downside198.08%
GradeFair
TypeGrowth
Risk assessment
Beta2.26
Volatility103.42%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.